U.S. market Closed. Opens in 6 hours 1 minute

FENC | Fennec Pharmaceuticals Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for FENC we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is poor, Growth is bad and Health is frighteningly weak.

Valuation (33%)

Company Industry
P/E Ratio (TTM) 48.50 -22.01
PEG Ratio (TTM) 4.36 15.69
P/S Ratio (TTM) 2.64 48.43
P/B Ratio (TTM) -95.16 18.71
P/FCF Ratio (TTM) 5.60 -2.79
Price to 5YR AVG Earnings Ratio -6.54 -3.21
Price to 5YR AVG FCF Ratio -8.70 -8.75

Profitability (45%)

Company Industry
ROA (TTM) 4.22% -5.02%
ROE (TTM) -52.10% 16.95%
Net Profit Margin (TTM) 5.43% -1,552.13%
ROIC 5YR AVG 607,351.11% 14.51%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 112.89% -9.98% -7.19%
Revenue 57.69% -33.33% 241.98%
Net Income 110.15% -22.42% -15.07%
Cash Flow 177.32% -26.37% -20.55%

Health (30%)

Company Industry
Current Ratio (TTM) 8.02 6.08
Quick Ratio (TTM) 7.75 5.80
D/E Ratio (TTM) -21.93 -15.32
Interest Coverage (TTM) 1.50 -1.96
Piotroski F-Score 1 5
Altman Z-Score N/A 13.86
LTL to 5YR AVG FCF -1.99 0.16
Shares Outstanding Growth 5YR AVG 7.13% 128.58%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙